Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.

Essers D, Schäublin M, Kullak-Ublick GA, Weiler S.

Eur J Clin Pharmacol. 2018 Nov 15. doi: 10.1007/s00228-018-2589-z. [Epub ahead of print]

PMID:
30430215
2.

Safety differentiation: emerging competitive edge in drug development.

Uteng M, Urban L, Brees D, Muller PY, Kullak-Ublick GA, Bouchard P, Tougas G, Chibout SD.

Drug Discov Today. 2018 Sep 19. pii: S1359-6446(18)30190-9. doi: 10.1016/j.drudis.2018.09.009. [Epub ahead of print] Review.

PMID:
30244081
3.

Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury.

Akhmedov A, Bonetti NR, Reiner MF, Spescha RD, Amstalden H, Merlini M, Gaul DS, Diaz-Cañestro C, Spescha RS, Semerano A, Giacalone G, Savarese G, Montecucco F, Kulic L, Nitsch RM, Matter CM, Kullak-Ublick GA, Sessa M, Lüscher TF, Beer JH, Liberale L, Camici GG.

J Cereb Blood Flow Metab. 2018 Aug 3:271678X18793266. doi: 10.1177/0271678X18793266. [Epub ahead of print]

PMID:
30073881
4.

Corrigendum to 'Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury' [Int. J. Cardiol. 260 (2018) 148-155].

Diaz-Cañestro C, Merlini M, Bonetti NR, Liberale L, Wüst P, Briand-Schumacher S, Klohs J, Costantino S, Miranda M, Schoedon-Geiser G, Kullak-Ublick GA, Akhmedov A, Paneni F, Beer JH, Lüscher TF, Camici GG.

Int J Cardiol. 2018 Nov 15;271:405. doi: 10.1016/j.ijcard.2018.07.004. Epub 2018 Jul 13. No abstract available.

PMID:
30007483
5.

Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors.

Visentin M, Torozi A, Gai Z, Häusler S, Li C, Hiller C, Schraml PH, Moch H, Kullak-Ublick GA.

Drug Metab Dispos. 2018 Aug;46(8):1129-1136. doi: 10.1124/dmd.118.081091. Epub 2018 May 24.

PMID:
29794161
6.

Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination.

Jödicke AM, Curkovic I, Zellweger U, Tomka IT, Neuer T, Kullak-Ublick GA, Roos M, Egbring M.

Ann Pharmacother. 2018 Oct;52(10):983-991. doi: 10.1177/1060028018775914. Epub 2018 May 11.

7.

Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.

Gai Z, Visentin M, Gui T, Zhao L, Thasler WE, Häusler S, Hartling I, Cremonesi A, Hiller C, Kullak-Ublick GA.

Mol Pharmacol. 2018 Aug;94(2):802-811. doi: 10.1124/mol.117.111047. Epub 2018 May 9.

PMID:
29743187
8.

Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury.

Diaz-Cañestro C, Merlini M, Bonetti NR, Liberale L, Wüst P, Briand-Schumacher S, Klohs J, Costantino S, Miranda M, Schoedon-Geiser G, Kullak-Ublick GA, Akhmedov A, Paneni F, Beer JH, Lüscher TF, Camici GG.

Int J Cardiol. 2018 Jun 1;260:148-155. doi: 10.1016/j.ijcard.2017.12.060. Erratum in: Int J Cardiol. 2018 Nov 15;271:405.

PMID:
29622432
9.

Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation.

Schadt HS, Wolf A, Mahl JA, Wuersch K, Couttet P, Schwald M, Fischer A, Lienard M, Emotte C, Teng CH, Skuba E, Richardson TA, Manenti L, Weiss A, Graus Porta D, Fairhurst RA, Kullak-Ublick GA, Chibout SD, Pognan F, Kluwe W, Kinyamu-Akunda J.

Toxicol Sci. 2018 May 1;163(1):265-278. doi: 10.1093/toxsci/kfy031.

PMID:
29432567
10.

Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort.

Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, Goepfert JC, Hackman F, King NMP, Kirby S, Kirby P, Marcinak J, Ormarsdottir S, Schomaker SJ, Schuppe-Koistinen I, Wolenski F, Arber N, Merz M, Sauer JM, Andrade RJ, van Bömmel F, Poynard T, Watkins PB.

Hepatology. 2018 Jan 22. doi: 10.1002/hep.29802. [Epub ahead of print]

PMID:
29357190
11.

Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5).

Visentin M, Gai Z, Torozi A, Hiller C, Kullak-Ublick GA.

Drug Metab Dispos. 2017 Dec;45(12):1240-1244. doi: 10.1124/dmd.117.077248. Epub 2017 Oct 6.

PMID:
28986476
12.

Drug-induced bile duct injury.

Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1498-1506. doi: 10.1016/j.bbadis.2017.08.033. Epub 2017 Sep 4. Review.

13.

Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage.

Gai Z, Chu L, Xu Z, Song X, Sun D, Kullak-Ublick GA.

Sci Rep. 2017 Aug 29;7(1):9815. doi: 10.1038/s41598-017-10168-6.

14.

TNF-α Deficiency Prevents Renal Inflammation and Oxidative Stress in Obese Mice.

Wang H, Li J, Gai Z, Kullak-Ublick GA, Liu Z.

Kidney Blood Press Res. 2017;42(3):416-427. doi: 10.1159/000478869. Epub 2017 Jul 7.

15.

Severe injection site reactions after subcutaneous administration of Sayana©.

Jödicke AM, Dahmke H, Damke B, Schäublin M, Kullak-Ublick GA, Weiler S.

Swiss Med Wkly. 2017 May 10;147:w14432. doi: 10.4414/smw.2017.14432. eCollection 2017.

16.

A MIR4646 associated methylation locus is hypomethylated in adolescent depression.

Boström AE, Ciuculete DM, Attwood M, Krattinger R, Nikontovic L, Titova OE, Kullak-Ublick GA, Mwinyi J, Schiöth HB.

J Affect Disord. 2017 Oct 1;220:117-128. doi: 10.1016/j.jad.2017.05.017. Epub 2017 May 17.

17.

Drug-induced liver injury: recent advances in diagnosis and risk assessment.

Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP.

Gut. 2017 Jun;66(6):1154-1164. doi: 10.1136/gutjnl-2016-313369. Epub 2017 Mar 23. Review.

18.

Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein-Coupled Receptor OGR1 (GPR68).

de Vallière C, Cosin-Roger J, Simmen S, Atrott K, Melhem H, Zeitz J, Madanchi M, Tcymbarevich I, Fried M, Kullak-Ublick GA, Vavricka SR, Misselwitz B, Seuwen K, Wagner CA, Eloranta JJ, Rogler G, Ruiz PA.

Cell Mol Gastroenterol Hepatol. 2016 Jun 25;2(6):796-810. doi: 10.1016/j.jcmgh.2016.06.003. eCollection 2016 Nov.

19.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

20.

Impact of Organic Cation Transporters (OCT-SLC22A) on Differential Diagnosis of Intrahepatic Lesions.

Visentin M, van Rosmalen BV, Hiller C, Bieze M, Hofstetter L, Verheij J, Kullak-Ublick GA, Koepsell H, Phoa SS, Tamai I, Bennink RJ, van Gulik TM, Stieger B.

Drug Metab Dispos. 2017 Feb;45(2):166-173. doi: 10.1124/dmd.116.072371. Epub 2016 Nov 30.

21.

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial.

Egbring M, Far E, Roos M, Dietrich M, Brauchbar M, Kullak-Ublick GA, Trojan A.

J Med Internet Res. 2016 Sep 6;18(9):e238. doi: 10.2196/jmir.6414.

22.

HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.

Stocker A, Hilbers ML, Gauthier C, Grogg J, Kullak-Ublick GA, Seifert B, Varga Z, Trojan A.

PLoS One. 2016 Jul 27;11(7):e0159176. doi: 10.1371/journal.pone.0159176. eCollection 2016.

23.

Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.

Gai Z, Visentin M, Hiller C, Krajnc E, Li T, Zhen J, Kullak-Ublick GA.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5573-80. doi: 10.1128/AAC.00907-16. Print 2016 Sep.

24.

Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes.

Krattinger R, Boström A, Lee SML, Thasler WE, Schiöth HB, Kullak-Ublick GA, Mwinyi J.

Life Sci. 2016 Jul 1;156:47-56. doi: 10.1016/j.lfs.2016.04.037. Epub 2016 May 10.

25.

Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.

Claro da Silva T, Hiller C, Gai Z, Kullak-Ublick GA.

J Steroid Biochem Mol Biol. 2016 Oct;163:77-87. doi: 10.1016/j.jsbmb.2016.04.006. Epub 2016 Apr 20.

26.

microRNA-192 suppresses the expression of the farnesoid X receptor.

Krattinger R, Boström A, Schiöth HB, Thasler WE, Mwinyi J, Kullak-Ublick GA.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1044-51. doi: 10.1152/ajpgi.00297.2015. Epub 2016 Apr 14.

27.

No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers.

Kullak-Ublick GA, Gubler C, Spanaus K, Ismair MG, Claro da Silva T, Jetter A.

Eur J Clin Pharmacol. 2016 Jul;72(7):797-805. doi: 10.1007/s00228-016-2050-0. Epub 2016 Mar 29.

28.

Bile acids in drug induced liver injury: Key players and surrogate markers.

Schadt HS, Wolf A, Pognan F, Chibout SD, Merz M, Kullak-Ublick GA.

Clin Res Hepatol Gastroenterol. 2016 Jun;40(3):257-266. doi: 10.1016/j.clinre.2015.12.017. Epub 2016 Feb 10. Review.

29.

Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.

Gai Z, Gui T, Hiller C, Kullak-Ublick GA.

J Biol Chem. 2016 Jan 29;291(5):2397-411. doi: 10.1074/jbc.M115.694323. Epub 2015 Dec 11.

30.

[5-0xoproline (pyroglutamic acid) acidosis and acetaminophen- a differential diagnosis in high anion gap metabolic acidosis].

Weiler S, Bellmann R, Kullak-Ublick GA.

Ther Umsch. 2015 Dec;72(11-12):737-41. doi: 10.1024/0040-5930/a000745. Review. German.

31.

Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.

Sigaroudi A, Kullak-Ublick GA, Weiler S.

Eur J Clin Pharmacol. 2016 Mar;72(3):377-8. doi: 10.1007/s00228-015-1991-z. Epub 2015 Dec 3. No abstract available.

32.

Too frequent low-dose methotrexate prescriptions: multicentre quality control and quality assurance with pre- and post-analysis.

Karlen S, Oertle M, Weiler S, Schneemann M, Eschmann E, Kullak-Ublick GA, Blaser J.

Swiss Med Wkly. 2015 Nov 24;145:w14218. doi: 10.4414/smw.2015.14218. eCollection 2015.

33.

[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].

Dahmke H, Kupferschmidt H, Kullak-Ublick GA, Weiler S.

Praxis (Bern 1994). 2015 Oct 14;104(21):1129-34. doi: 10.1024/1661-8157/a002160. German.

34.

Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis.

Reiber C, Senn O, Müller D, Kullak-Ublick GA, Corti N.

Ther Drug Monit. 2015 Oct;37(5):634-40. doi: 10.1097/FTD.0000000000000196.

35.

Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2.

Visentin M, Stieger B, Merz M, Kullak-Ublick GA.

J Pharmacol Exp Ther. 2015 Nov;355(2):145-51. doi: 10.1124/jpet.115.227546. Epub 2015 Sep 1.

36.

The pH-sensing receptor OGR1 improves barrier function of epithelial cells and inhibits migration in an acidic environment.

de Vallière C, Vidal S, Clay I, Jurisic G, Tcymbarevich I, Lang S, Ludwig MG, Okoniewski M, Eloranta JJ, Kullak-Ublick GA, Wagner CA, Rogler G, Seuwen K.

Am J Physiol Gastrointest Liver Physiol. 2015 Sep 15;309(6):G475-90. doi: 10.1152/ajpgi.00408.2014. Epub 2015 Jul 23.

37.

Drug-induced liver injury: the dawn of biomarkers?

Weiler S, Merz M, Kullak-Ublick GA.

F1000Prime Rep. 2015 Mar 3;7:34. doi: 10.12703/P7-34. eCollection 2015. Review.

38.

G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation.

de Vallière C, Wang Y, Eloranta JJ, Vidal S, Clay I, Spalinger MR, Tcymbarevich I, Terhalle A, Ludwig MG, Suply T, Fried M, Kullak-Ublick GA, Frey-Wagner I, Scharl M, Seuwen K, Wagner CA, Rogler G.

Inflamm Bowel Dis. 2015 Jun;21(6):1269-81. doi: 10.1097/MIB.0000000000000375.

39.

Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase.

Gerster R, Eloranta JJ, Hausmann M, Ruiz PA, Cosin-Roger J, Terhalle A, Ziegler U, Kullak-Ublick GA, von Eckardstein A, Rogler G.

Cell Mol Gastroenterol Hepatol. 2014 Dec 26;1(2):171-187.e1. doi: 10.1016/j.jcmgh.2014.12.006. eCollection 2015 Mar.

40.

Liver safety assessment in special populations (hepatitis B, C, and oncology trials).

Kullak-Ublick GA, Merz M, Griffel L, Kaplowitz N, Watkins PB.

Drug Saf. 2014 Nov;37 Suppl 1:S57-62. doi: 10.1007/s40264-014-0186-3. Review.

41.

Methodology to assess clinical liver safety data.

Merz M, Lee KR, Kullak-Ublick GA, Brueckner A, Watkins PB.

Drug Saf. 2014 Nov;37 Suppl 1:S33-45. doi: 10.1007/s40264-014-0184-5. Review.

42.

Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese mice.

Chin SH, Item F, Wueest S, Zhou Z, Wiedemann MS, Gai Z, Schoenle EJ, Kullak-Ublick GA, Al-Hasani H, Konrad D.

Diabetes. 2015 Apr;64(4):1131-41. doi: 10.2337/db14-0779. Epub 2014 Oct 16.

43.

Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Basler M, Jetter A, Fink D, Seifert B, Kullak-Ublick GA, Trojan A.

Breast Care (Basel). 2014 Jul;9(3):182-7. doi: 10.1159/000363426.

44.

Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney.

Gai Z, Hiller C, Chin SH, Hofstetter L, Stieger B, Konrad D, Kullak-Ublick GA.

Biochim Biophys Acta. 2014 Sep;1842(9):1870-8. doi: 10.1016/j.bbadis.2014.07.001. Epub 2014 Jul 10.

45.

The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes.

Schaffner CA, Mwinyi J, Gai Z, Thasler WE, Eloranta JJ, Kullak-Ublick GA.

Liver Int. 2015 Apr;35(4):1152-61. doi: 10.1111/liv.12558. Epub 2014 Apr 29.

46.

Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.

Mwinyi J, Vokinger K, Jetter A, Breitenstein U, Hiller C, Kullak-Ublick GA, Trojan A.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1181-8. doi: 10.1007/s00280-014-2453-5. Epub 2014 Mar 29.

47.

Rivaroxaban postmarketing risk of liver injury.

Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA.

J Hepatol. 2014 Aug;61(2):293-300. doi: 10.1016/j.jhep.2014.03.026. Epub 2014 Mar 28.

48.

[A 78-year-old female patient with dizziness, apraxia and seizure under proton pump inhibitor therapy].

Piezzi V, Kullak-Ublick GA, Glisenti P.

Internist (Berl). 2014 Feb;55(2):199-205. doi: 10.1007/s00108-013-3419-0. German.

PMID:
24419536
49.

Atypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data.

Meli M, Rauber-Lüthy C, Hoffmann-Walbeck P, Reinecke HJ, Prasa D, Stedtler U, Färber E, Genser D, Kupferschmidt H, Kullak-Ublick GA, Ceschi A.

Eur J Pediatr. 2014 Jun;173(6):743-50. doi: 10.1007/s00431-013-2241-y. Epub 2013 Dec 27.

PMID:
24370666
50.

Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates.

Curkovic I, Egbring M, Kullak-Ublick GA.

Dig Dis. 2013;31(3-4):368-73. doi: 10.1159/000354699. Epub 2013 Nov 14. Review.

Supplemental Content

Loading ...
Support Center